Novo Nordisk disclosed several key updates from its cardiometabolic and hematology pipelines Wednesday as the drugmaker ...

It took decades to get to the GLP-1 breakthrough in obesity treatment. Now, the biopharma industry is clamoring over the field's next frontier: staving off the losses ...

Response Pharmaceuticals believes its experimental drug can lessen the persistent weight gain associated with antipsychotics.

Catalent reported a slight revenue upswing during its latest quarterly results, which CEO Alessandro Maselli attributed to ...

Zealand is po­si­tion­ing the drug as a po­ten­tial stand­alone re­place­ment for GLP-1s or as the first med­i­cine that ...

Novo Nordisk’s once-a-day sickle cell disease drug etavopivat cut the rate of pain crises in a yearlong mid-stage study. The ...

Johnson & Johnson’s CD38 inhibitor Darzalex showed a benefit in delaying or preventing disease progression in patients with ...

Beam Therapeutics gave an initial look at the first handful of patients who received its experimental gene-edited treatment ...

Troubled mental health startup Cerebral has agreed to pay nearly $3.7 million in connection with its efforts to encourage unauthorized prescriptions of ADHD medications and other ...

As for­mer Pres­i­dent Don­ald Trump like­ly re­turns to pow­er — the As­so­ci­at­ed Press pro­ject­ed his pres­i­den­tial vic­to­ry Wednes­day morn­ing — the bio­phar­ma in­dus­try may see the door … ...

Sanofi’s BTK inhibitor rilzabrutinib helped 23% of adults with a rare autoimmune blood disorder achieve target platelet counts in a Phase 3 trial, compared to zero patients in the placebo ...

Syndax Pharmaceuticals’ $350M deal with Royalty Pharma: The agreement is based on US sales of Niktimvo, Syndax’s graft-versus-host disease ...